Association of First-in-class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage Iv Melanoma

DOI: 10.1001/jamaoncol.2017.3462

,

Issn Print: 2374-2437

Publication Date: 2018/01/01

Andrew J. Sinnamon; Madalyn G. Neuwirth; Phyllis A. Gimotty; Tara C. Gangadhar; Ravi K. Amaravadi; Lynn M. Schuchter; Giorgos C. Karakousis

Author Information: Department of Surgery, Division of Endocrine and Oncologic Surgery, Hospital of the University of Pennsylvania, Philadelphia


		Checking for direct PDF access through Ovid

Abstract unavailable for this article.


		Loading Related Articles

Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma